• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » Suvorexant prevents delirium [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.

Suvorexant prevents delirium [60 Sec Psych]

September 19, 2020

We often worry about sleep meds in the medically ill, and there’s plenty of cause to: falls, respiratory suppression, and confusion. On the other hand, sleep disruption is a major risk factor for delirium, and there’s growing evidence that some sleep meds – ramelteon, melatonin, but not the benzos or z-hypnotics -  can prevent this sequale of surgery and major medical illness. This study adds the orexin antagonist Suvorexant/Bellsomra to that list. [Study Link]


Published On: 9/16/2020


Duration: 2 minutes, 55 seconds


Transcript: 

We often worry about sleep meds in the medically ill, and there’s plenty of cause to: falls, respiratory suppression, and confusion. On the other hand, sleep disruption is a major risk factor for delirium, and there’s growing evidence that some sleep meds – ramelteon, melatonin, but not the benzos or z-hypnotics - can prevent this sequale of surgery and major medical illness. This study adds the orexin antagonist Suvorexant/Bellsomra to that list.

It was a metaanalysis of 7 trials – 3 were the classic prospective RCTs, 4 were retrospective case-control studies. Generally they compared patients who took Suvorexant with others in the hospital or ICU setting. Overall, treatment with Suvorexant reduced delirium by 30%, and delayed the time to delirium with a moderate effect size of 0.44. The limitation was the inclusion of retrospective studies, although the effect was a little larger in the prospective studies and all studies had a positive effect. Also the total size was small for a meta-analysis, 487 patients. The analysis received no industry funding.

Suvorexant may reduce delirium by improving sleep or by blocking orexin, levels of which are elevated in delirium and are associated with increased parasympathetic and inflammatory activity.

Suvorexant, its cousin lemborexant, ramelteon, melatonin, and low-dose doxepin are the only sleep meds that aren’t considered potentially inappropriate in the elderly by the Beers Criteria. So far, 3 of those Suvorexant ramelteon and melatonin, have evidence to prevent delirium. We’ll have more coverage of the other two - ramelteon and melatonin – in our October issue.

Got feedback? Take the podcast survey.
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.